All In Biotech

Drug Trial Radar · NCT06777433

Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

An Open-Label, Single Dose, Single Arm, Multicenter Phase 2b Study to Establish the Imaging Performance of RAD101 Positron Emission Tomography (PET) in Participants With Suspected Recurrent Brain Metastases From Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 13, 2024

Primary completion

Apr 23, 2026

Study completion Oct 2026

Sponsor

Lead sponsor
Radiopharm Theranostics, LtdIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Jan 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid tumors. The study consists of a 4-week Screening Period, a 3-day Imaging and Safety Follow-Up Period, and a Data Collection Period of up to 6 months. Participant eligibility will be determined during the Screening Period and eligible participants will be enrolled in the study. On Day 1, the enrolled participants will receive a single dose of the investigational medicinal product (IMP), RAD101. Participants will then proceed with a whole brain PET scan. A high-resolution Magnetic Resonance Imaging (MRI) will be performed in joint acquisition with PET or separately on the same day, or on the day prior to or the day following RAD101 administration. For applicable study sites where PK samples will be collected, whole body PET scans will be performed, blood samples will be drawn, and urine will be collected throughout the scanning period. A phone follow-up will be performed on Day 3 (+ 1 day). Participants will have follow-up (longitudinal) MRI (otherwise CT) scans (longitudinal imaging) and/ or a biopsy according to their Standard of Care (SoC). The longitudinal image results, and details of the biopsy if performed as part of SoC (i.e., location and histopathology results), will be collected during the 6- month Data Collection Period.

Conditions

  • Brain Metastases From Solid Tumors

Interventions

  • RAD101 (18F-FPIA)Drug

    A single dose of 18F-RAD101 with a maximum of 370 MBq (10 mCi) administered as a slow IV bolus injection over a maximum of 30 seconds, followed by a saline flush.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concordance between RAD101 PET/MRI and MRI with macrocyclic gadoliniumTime frame: 1 Week
  2. Concordance between RAD101 PET/MRI and MRI with macrocyclic gadoliniumTime frame: 1 Week
  3. Concordance between RAD101 PET/MRI and MRI with macrocyclic gadoliniumTime frame: 1 Week

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Ascension Illinois Oncology Research

    Hoffman Estates, Illinois

  • Goshen Center for Cancer Care

    Goshen, Indiana

  • University of Michigan

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • BAMF Health

    Grand Rapids, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.